December 1st 2025
Former CBER chief calls claims "misrepresentation." ID experts Offit and Osterholm criticize timing ahead of CDC advisory committee meeting next week.
FDA Advisers Endorse Natalizumab (Tysabri) for Crohn's Disease
August 2nd 2007GAITHERSBURG, Md. -- FDA advisers have recommended approval of the problem-ridden multiple sclerosis drug natalizumab (Tysabri) for treatment of moderate to severe Crohn's disease, but only with extensive safety monitoring.